NK-1 Drug Fills Motion Sickness Gap

Tradipitant demonstrates 50% to 70% risk reduction for vomiting incidence during motion exposure in phase 3 trials.

1

The FDA approved NEREUS (tradipitant) for preventing motion-induced vomiting in adults, marking the first new treatment in over 40 years.
2

Tradipitant significantly reduced vomiting incidence in phase 3 studies, with rates of 18%-20% versus 44% for placebo in Motion Syros.
3

The drug acts as a neurokinin-1 receptor antagonist, targeting the substance P pathway involved in motion-induced nausea.
4

Common adverse reactions include somnolence and fatigue, with warnings about impaired abilities for driving or operating machinery.
5

Vanda Pharmaceuticals is developing tradipitant for additional indications, including gastroparesis and nausea from diabetes treatments.

1